Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2507-2511

  Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Correlates; HIV; Neutralizing antibodies; Sieve; Vaccines

Indexed keywords

EPITOPE; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; VIRUS ENVELOPE PROTEIN; BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

BLOOD SAMPLING; CELLULAR IMMUNITY; CLADISTICS; CLINICAL EFFECTIVENESS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENVELOPE GENE; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; NOTE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; IMMUNOLOGY; MEDICAL RESEARCH; PROCEDURES; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HIV ANTIBODIES; HUMANS; TREATMENT OUTCOME;

EID: 84908517826     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28950     Document Type: Note

References (59)

1. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12; PMID:17922394; http://dx.doi.org/10.1086/522428
2. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9; http://dx.doi.org/10.1086/589862; PMID:18558875
3. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7; http://dx.doi.org/10.1093/cid/cis238; PMID:22437237
4. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-44; PMID:20192810; http://dx.doi.org/10.1146/annurev-immunol-030409-101256
5. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-55; PMID:16551249; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090605
6. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5:204-10; http://dx.doi.org/10.1038/5568; PMID:9930869
7. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10; http://dx.doi.org/10.1038/72318; PMID:10655111
8. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-4; http://dx.doi.org/10.1038/nm.1974; PMID:19525965
9. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-6; PMID:10655110; http://dx.doi.org/10.1038/72309
10. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-30; PMID:11836389; http://dx.doi.org/10.1128/jvi.76.5.2123-2130.2002
11. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 2003; 100:15131-6; PMID:14627745; http://dx.doi.org/10.1073/pnas.2436476100
12. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301-9; PMID:12556683; http://dx.doi.org/10.1097/00002030-200302140-00003
13. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.; MOPHTAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID:19843557
14. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; http://dx.doi.org/10.1056/NEJMoa1113425; PMID:22475592
15. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013; 8:e75665; http://dx.doi.org/10.1371/journal.pone.0075665; PMID:24086607
16. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9:e87572; http://dx.doi.org/10.1371/journal.pone.0087572; PMID:24504509
17. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86:11521-32; http://dx.doi.org/10.1128/JVI.01023-12; PMID:22896626
18. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang Z-Y, Seaton KE, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39
19. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast A-S, Schoen MK, Rolland M, Suscovich TJ, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014 Mar 19;6(228):228ra38
20. Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-89; http://dx.doi.org/10.1097/QAD.0b013e328342ff93; PMID:21297424
21. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013; 66:391-400; http://dx.doi.org/10.1016/j.jinf.2012.10.026; PMID:23103289
22. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, et al.; The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-8; PMID:8568294; http://dx.doi.org/10.1093/infdis/173.2.340
23. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16:2019-35; PMID:11153085; http://dx.doi.org/10.1089/088922200750054756
24. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, et al.; NIAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407-15; PMID:9875578; http://dx.doi.org/10.1097/00002030-199818000-00009
25. Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202:595-605; http://dx.doi.org/10.1086/654816; PMID:20608874
26. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206:431-41; http://dx.doi.org/10.1093/infdis/jis367; PMID:22634875
27. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014; 28:163-9; http://dx.doi.org/10.1097/QAD.0000000000000106; PMID:24361678
28. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-70; PMID:19525964
29. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412-25; PMID:22999947; http://dx.doi.org/10.1016/j.immuni.2012.08.012
30. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012; 12:396-407; http://dx.doi.org/10.1016/j.chom.2012.09.008; PMID:23084910
31. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705-42; PMID:23330954; http://dx.doi.org/10.1146/annurev-immunol-032712-095916
32. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341:1199-204; PMID:24031012; http://dx.doi.org/10.1126/science.1241144
33. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009; 485:395-405; PMID:19020839; http://dx.doi.org/10.1007/978-1-59745-170-3-26
34. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 2013; http://dx.doi.org/10.1016/j.jim.2014.02.013, In press; PMID:24291345.
35. Sarzotti-Kelsoe M, Daniell X, Todd CA, Bilska M, Martelli A, Labranche C, Perez LG, Ochsenbauer C, Kappes JC, Rountree W, et al. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods 2014; In press; PMID:24607608; http://dx.doi.org/10.1016/j.jim.2014.02.013.
36. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-48; PMID:19439467; http://dx.doi.org/10.1128/JVI.00110-09
37. Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, Huang Y, Wang M, Li G, Brown R, Wood B, et al. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods 2012; 375:57-67; http://dx.doi.org/10.1016/j.jim.2011.09.007; PMID:21968254
38. Ozaki DA, Gao H, Todd CA, Greene KM, Montefiori DC, Sarzotti-Kelsoe M. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS One 2012; 7:e30963; PMID:22303476; http://dx.doi.org/10.1371/journal.pone.0030963
39. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25; http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005; PMID:16051804
40. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776-90; http://dx.doi.org/10.1128/JVI.01730-06; PMID:16971434
41. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, de Souza MS, Birx DL, McCutchan FE, Polonis VR. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol 2005; 79:6089-101; http://dx.doi.org/10.1128/JVI.79.10.6089-6101.2005; PMID:15857994
42. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2014; 88:2489-507; http://dx.doi.org/10.1128/JVI.02853-13; PMID:24352443
43. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79:10103-7; http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005; PMID:16051803
44. Rolland M, Gilbert P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses 2012; 28:400-4; http://dx.doi.org/10.1089/aid.2011.0240; PMID:21902593
45. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417-20; http://dx.doi.org/10.1038/nature11519; PMID:22960785
46. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366-71; http://dx.doi.org/10.1038/nm.2316; PMID:21358627
47. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014; 505:502-8; http://dx.doi.org/10.1038/nature12893; PMID:24352234
48. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-70; http://dx.doi.org/10.1128/JVI.02660-07; PMID: 18256145
49. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012; 8:e1002721; http://dx.doi.org/10.1371/journal.ppat.1002721; PMID:22693447
50. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, et al.; CHAVI Clinical Core B. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-72; http://dx.doi.org/10.1084/jem.20090365; PMID:19487423
51. Moore PL, Gray ES, Morris L. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS 2009; 4:358-63; http://dx.doi.org/10.1097/COH.0b013e32832ea7e8; PMID:20048698
52. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/ founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-89; http://dx.doi.org/10.1084/jem.20090378; PMID:19487424
53. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3; PMID:19012954
54. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5:e1000274; http://dx.doi.org/10.1371/journal.ppat.1000274; PMID:19165325
55. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping L-H, Athreya GS, Treurnicht FK, Keele BF, Wood N, et al.; CAPRISA Acute Infection Study Team; Center for HIV-AIDS Vaccine Immunology Consortium. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83:3556-67; http://dx.doi.org/10.1128/JVI.02132-08; PMID:19193811
56. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 2010 May 13;6(5):e1000890
57. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; http://dx.doi.org/10.1086/428404
58. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77; PMID:15688279; http://dx.doi.org/10.1086/428405
59. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-603; PMID:17475891; http://dx.doi.org/10.4049/jimmunol.178.10.6596